Background
==========

The London Declaration on Neglected Tropical Diseases (NTD) brought an international awareness and commitment to combat NTD that has since resulted worldwide in increased pledges of drug donations \[[@B1]\]. However, these worldwide prospects for more frequent mass drug administration (MDA) campaigns warrant caution, particularly for soil-transmitted helminths (STH, *Ascaris lumbricoides, Trichuris trichiura* and hookworms). First, MDA programs to control STH predominantly rely on just one group of anthelminthics, the benzimidazole drugs (albendazole (ALB) and mebendazole (MEB)), which make these campaigns highly vulnerable to the development of anthelminthic resistance \[[@B2]-[@B5]\]. Second, these benzimidazole drugs cannot be administered to women in the first trimester of pregnancy due to their teratogenicity \[[@B6]\]. Thirdly, a single dose of the benzimidazole drugs against the different STH is often not sufficient to clear infections completely, showing primarily poor efficacy against *T. trichiura* infections, especially when levels of infection intensity are high \[[@B7]-[@B10]\]. Despite the pressing and obvious need for alternative drugs, there are currently no compounds available on the market that outcompete the benzimidazoles in terms of efficacy, safety and feasibility \[[@B11]-[@B15]\].

Studies going back many decades have indicated that the cysteine proteinases (CPs) from papaya (*Carica papaya*), collectively known as 'papain', have the ability to control gastrointestinal parasites in humans, including STH \[[@B16]-[@B18]\]. The CPs of papaya reside in the latex that is present in most parts of the plant (but not the ripe fruit) and is released upon injury. Plant derived CPs are thought to help protect the developing and unripe fruits from exploitation by plant-parasitic nematodes and by arthropod pests \[[@B19]-[@B21]\]. It is known that there are four CPs in the latex, of which papain is the least abundant \[[@B22]\]. Confusingly, crude preparations of papaya latex CPs are often referred to as 'papain', but we will use the term 'papaya CPs'. The anthelmintic application of papaya CPs in public health subsequently received very little attention, probably due to competition with the upcoming synthetic anthelmintic drugs. However, it is already apparent that papaya CPs are most likely safe and tolerable, as they are already present in the human food chain (e.g., meat tenderizers, beer clarifiers, and enhancers of food item flavours \[[@B23],[@B24]\]. Second, papaya CPs with a molecular weight of \~23.5 kDa are very unlikely to be absorbed without first being broken down to peptides, and hence can probably be administered to women at an early stage of pregnancy. In addition, papaya CPs have a different mode of action to current anthelmintics (digestion of helminth cuticles) \[[@B25]\], and hence they are a serious contender for an alternative backup drug should anthelminthic resistance occur against the benzimidazoles. They are likely to have more than one target site on the cuticle, making rapid development of resistance very unlikely. Finally, their impact is not restricted to STH, but may have also a clear impact on other gastro-intestinal parasites, as shown by the in vitro experiments on animal tapeworms \[[@B25],[@B26]\].

With increasing reports of resistance against current synthetic anthelminthics in veterinary medicine and lack of efficacy in some cases, the efficacy of papaya CPs has mainly been evaluated against gastrointestinal nematodes in sheep (*Haemonchus contortus*) \[[@B27]\] and also in various in vivo laboratory models \[[@B28]-[@B32]\]. In the present study, we evaluated the efficacy of papaya CPs against experimental *T. suis* infections in pigs, the latter being an appropriate and relevant animal model for human trichuriasis. This host-parasite combination allows the assessment of efficacy by means of reduction in both egg counts and adult worm counts. In addition, we verified whether egg counts in stool are an appropriate proxy for worm burden.

Methods
=======

Trial design
------------

Two randomized control efficacy trials were conducted. In the first trial, we assessed how a single-oral dose of 450 μmol active papaya CPs compares with a single-oral dose of 400 mg ALB (proof-of-principle trial) for low and high intensity *T. suis* infections. In the second trial, we determined to what extent we could reduce the dose of papaya CPs without loss of the efficacy levels obtained by administering 450 μmol papaya CP (dose--response trial).

In each of these trials, Rattlerow Senghers hybrid piglets between 8--12 weeks were infected with *T. suis* eggs containing infectious larvae at day (D)-42. At D-1, levels of egg excretion by means of fecal egg counts (FECs) were determined, after which animals were randomized to a treatment group stratifying for level of egg excretion. The treatments were given on D0. By this time, the mean body weight of the pigs was 43.3 kg (95% confidence interval (95% CI): 40.2-46.2). Each treatment group included six animals. Finally, at D + 6 FECs were determined again and at D + 7 all the animals were sacrificed and the total number of adult *T. suis* was assessed. Although each of the two trials followed this general format, they differed in the number of *T. suis* (inoculum), the product and the dose of the product administered. In the proof-of-principle trial, we assessed the efficacy of a single-oral dose of 450 μmol papaya CPs and a single-oral dose of 400 mg ALB against low (inoculum = 300 embryonated *T. suis* eggs) and heavy intensity *T. suis* infections (inoculum = 3,000 embryonated *T. suis* eggs). In the dose--response trial, we assessed the efficacy of a single oral-dose of 45 (10% of the dose evaluated in the proof-of-principle trial), 115 (25%), 225 (50%) and 450 μmol (100%) of papaya CPs against high levels of infection intensity (inoculum = 3,000 *T. suis* eggs). The Ethical Committee of the Faculty of Veterinary Medicine, Ghent University (Belgium) approved the study protocol of both trials (Trial 1: EC2011/171; Trial 2 EC2012/178). The animals were bred, raised and housed at the Animal Experimental Unit (*Biocentrum Agrivet*) of the Faculty of Veterinary Medicine, Ghent University, Belgium.

Papaya cysteine proteinase and albendazole
------------------------------------------

A supernatant from papaya latex enriched in CP activity was prepared as described \[[@B27]\]. Briefly, spray-dried *C. papaya* latex (Enzymase P1, Enzymase International S.A., 33 rue Jean-Baptiste BAECK - bte 3, B - 1190 Brussels, Belgium) was suspended in water then centrifuged at 17,700 × *g*. The supernatant was taken and concentrated by dialysis over polyethylene glycol 20,000. The concentrated material was aliquotted into individual containers and freeze-dried. Sample aliquots were taken at various time-points, weighed, and the concentration of active CP was determined by active-site titration with the CP inactivator E-64 (L-*trans*-epoxysuccinyl-leucylamido 4-guanidino butane -- Sigma Aldrich) \[[@B33]\]. Once aliquotted and freeze-dried, there was no detectable deterioration of enzyme activity over a period of at least 2 years, the specific activity of the material remaining at 10 μmol/g. The 400 mg ALB originated from GlaxoSmithKline Pharmaceuticals Limited, India.

Inoculation of *T. suis* eggs
-----------------------------

For each animal, the inoculum of 300 or 3,000 embryonated *T. suis* eggs was suspended in 5 ml of tap water, and subsequently administered directly into the stomach of the animal by gavage. To avoid accumulation of the *T. suis* eggs, the tube used to gavage was flushed with 10 ml of tap water before inoculating the next animal in the infection sequence. The *T. suis* eggs were kindly provided by Peter Nejsum and Stig Milan Thamsborg (Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1870 Frederiksberg C, Denmark).

Administration of papaya CPs and ALB
------------------------------------

Both papaya CPs and ALB tablets were crushed to powder using a pestle and mortar. Subsequently, the powder was suspended in tap water. The volume in which the papaya CPs was suspended ranged from 20 ml (45 μmol) to 150 ml (450 μmol). One ALB tablet was suspended in 20 ml of tap water. Both papaya CPs and ALB were administered directly into the stomach of the animal by gavage. The control group received 30 ml of tap water administered directly into the stomach by gavage. To avoid accumulation of the products, the tube used to gavage was flushed with 10 ml of tap water before inoculating the following animal. In addition to this, a separate tube was used for each treatment group to avoid cross-contamination.

Parasitological examination
---------------------------

### Assessment of FEC

FECs were determined using the McMaster egg counting method based on a protocol described by the Ministry of Agriculture, Fisheries, and Food (1986) \[[@B34]\]. Briefly, four grams of stool were suspended in 60 ml of saturated salt solution at room temperature (density \~ 1.2), prepared by adding NaCl to 5 l of warm distilled water (40--50°C) until no more salt went into solution and the excess settled on the bottom of the container). The fecal suspension was poured three times through a wire mesh (aperture of 250 μm) to remove large debris. Then, 0.5 ml aliquots were added to each of the two chambers of a McMaster slide ( <http://www.mcmaster.co.za>). Both chambers were examined under a light microscope using a 100x magnification and the FECs, expressed as eggs per gram of stool (EPG), were obtained by multiplying the total number of eggs by 50.

### Assessment of total adult T. suis worm counts

After sacrificing the animals, the large intestine (from caecum to rectum) was removed from the abdominal cavity. Then, the large intestine was opened longitudinally and rinsed with water to remove the content. The content of the intestine was further thoroughly washed on wire mesh (aperture of 800 μm), withholding the adult *T. suis*. Finally, adult *T. suis* worms were counted both in situ in the mucosa of the large intestine and in the contents of the intestine. To obtain the total adult *T. suis* worm counts (WC), the number of adult worms found in the mucosa of the large intestine was added to the number of worms found in the content of the intestine.

Statistical analysis
--------------------

Statistical analysis consisted of three parts. First, we verified whether animals were successfully randomized based on FECs. To this end, arithmetic mean FEC at D-1 was summarized for each of the different treatment groups in the two trials (in the first trial this was done for each level of infection intensity separately). Corresponding 95% confidence intervals were determined by bootstrap analysis (10,000 iterations). Differences in FECs at D-1 across the treatment groups were evaluated by a permutation test based on the F-statistic (10,000 iterations). Second, we report the efficacy of the different treatment regimens against *T. suis* infections in each trial by means of egg reduction rate (ERR) at D + 6 and the adult *T. suis* worms at D + 7 reduction rate (WRR) compared to the control group using the formulae below:

$$\begin{array}{ll}
{\mspace{1170mu}\text{ERR}} & {= 100\%} \\
 & {\quad \times \mspace{9mu}\left( {1 - \frac{\text{arithmetric\ mean\ of\ FECs\ at}\mspace{9mu} D + 6\mspace{9mu}\text{in\ the\ treatment\ group}}{\text{arithmetric\ of\ FECs\ at}\mspace{9mu} D + 6\mspace{9mu}\text{in\ the\ control\ group}}} \right)} \\
{\mspace{1170mu}\text{WRR}} & {= 100\%} \\
 & {\quad \times \mspace{9mu}\left( {1‒\frac{\text{arithmetric\ mean\ of\ WCs\ at}\mspace{9mu} D + 7\mspace{9mu}\text{in\ the\ treatment\ group}}{\text{arithmetric\ mean\ of\ WCs\ at}\mspace{9mu} D + 7\mspace{9mu}\text{in\ the\ control\ group}}} \right)} \\
\end{array}$$

Corresponding 95% confidence intervals were determined by bootstrap analysis (10,000 iterations). In the proof-of-principle trial, differences in efficacy between a single-oral dose of CPs and ALB were evaluated for each of the two levels of infection intensity using a permutation test based on the t-statistic (10,000 iterations). For the dose--response trial, any difference in efficacy between the four doses of CPs was evaluated, using a permutation test based on the t-statistic (10,000 iterations). Tukey's method was applied for multiple comparisons. Third, we evaluated whether FECs are an appropriate proxy for worm burden. To this end, we determined the correlations between the WC at D+7 and the corresponding FECs at D+6, for all animals in both trials by calculating the Pearsons' correlation coefficient. The statistical analysis was conducted in the statistical software R (version 3.0.1, 2013, The R Foundation for Statistical Computing Platform). The level of significance for each test was set at *p* ≤0.05.

Results
=======

Proof-of-principle trial
------------------------

Table  [1](#T1){ref-type="table"} summarizes the number of animals, mean FECs at D-1, the mean FECs at D+6 and the mean WCs at D+7 for each of the three treatment groups (single-oral dose of 450 μmol papaya CPs \[CP450\], single-oral dose of 400 mg ALB, control), and the efficacy of CP450 and ALB for low and high intensity *T. suis* infections, separately. One animal in the CP450 group inoculated with 3,000 *T. suis* eggs died during the trial. Autopsy did not reveal any causal association between the CP450 treatment and death. In the remaining groups, all 6 animals completed the trial. The mean FECs at D-1 for animals inoculated with 300 eggs, ranged from 8.3 EPG (95% CI: 0.0; 25.0) in both the P450 and ALB group to 16.7 EPG (95% CI: 0.0; 50.0) in the control group. For animals inoculated with 3,000 eggs, the mean FEC at D-1 ranged from 366.7 EPG (95% CI: 58.3; 800.0) in the control group to 483.3 (95% CI: 116.7; 916.7) in the ALB. For both levels of infection intensity, there was no significant difference in FEC at D-1 across the different treatment groups (F~low~ = 0.17, *p* = 0.78, F~high~ = 0.08, *p* = 0.93). The mean WC at D+7 in the control animals inoculated with 300 eggs was 131.5 (95% CI: 107.2; 161.3, recovery rate of 43.8% \[95% CI: 35.7; 53.8\]), for the control animals inoculated with 3,000 eggs the mean WC equaled 1,142.2 (95% CI: 893.0; 1,419.0, recovery of 38.1% \[95% CI: 29.8; 47.3\]). The ratio of mean FECs at D+6 and WCs at D+7 in the control animals inoculated with 3,000 eggs and the control animals inoculated with 300 eggs was 18.6 \[95% CI: 5.2; 57.0\] and 8.7 \[95% CI: 6.3; 11.8\], respectively.

###### 

**The efficacy of papaya CPs and albendazole against low and high intensity*T. suis*infections**

                                                       **n**   **Mean FECs at D-1 (EPG) (95% CI)**   **Mean FECs at D+6 (EPG) (96% CI)**   **ERR (%) (95% CI)**   **Mean WCs at D7 (95% CI)**   **WRR (%) (95% CI)**
  ---------------------------------------------------- ------- ------------------------------------- ------------------------------------- ---------------------- ----------------------------- ----------------------
  *Low infection intensity (inoculum = 300 eggs)*                                                                                                                                               
    CP450                                              6       8.3(0.0; 25.0)                        8.3(0.0; 25.0)                        98.3(92.7; 100)        1.3(0.2; 2.8)                 99.0\*(97.7; 99.9)
    ALB                                                6       8.3(0.0; 25.0)                        175.0(16.7; 358.3)                    64.4(-15.8; 96.3)      80.2(40.8; 122.0)             39.0\*(2.4; 69.1)
    Control                                            6       16.7(0; 50.0)                         491.7(183.3; 800.0)                   \_                     131.5(107.2; 161.3)           \_
  *High infection intensity (inoculum = 3,000 eggs)*                                                                                                                                            
    CP450                                              5\*\*   420.0(60.0; 780.0)                    100.0(10.0; 230.0)                    98.9\*(95.5; 99.9)     29.2(3.2; 63.2)               97.4\*(94.3; 99.7)
    ALB                                                6       483.3(116.7; 916.7)                   3800.0(1908.3; 5666.7)                59.0\*(-47.0; 83.4)    877.2(597.0; 1,094.3)         23.2\*(-7.8; 49.7)
    Control                                            6       366.7(58.3; 800.0)                    9266.7(2683.3; 17416.7)               \_                     1142.2(893.0; 1,419.0)        \_

The fecal egg counts (FEC) at day (D) -1, mean worm counts (WC) at D+7 and the reduction in WC at D+7 compared to the control group (WCR).

\*pair-wise comparison between CP450 and ALB revealed a significant difference with *p*-value \<0.01; \*\*One animal which received 3,000 eggs of *T. suis* and which was assigned to the CP450 treatment died in the course of trial. Autopsy did not reveal any causal association between the treatment and death.

A single-oral dose of P450 was highly efficacious, resulting in a ERR and WRR of almost 100% for both low (ERR: 98.3 \[95% CI: 92.7; 100\]; WRR: 99.0% \[95% CI: 97.7; 99.9\]) and high intensity infections (ERR: 98.9 \[95% CI: 95.5; 99.9\]; WRR: 97.4%% \[95% CI: 94.3; 99.7\]). A single-oral dose of ALB showed poor efficacy against both levels of infection intensity (low infection intensity: ERR: 64.4% \[95% CI: -15.8; 96.3\]; WRR: 39.0% \[95% CI: 2.4; 69.1\], high infection intensity: ERR: 59.0% \[95% CI: -47.0; 83.4\]; WRR: 23.2% \[95% CI: -7.8; 49.7\]). For both levels of infection intensity, a single-oral dose of P450 was significantly more efficacious compared to a single-oral dose of ALB by means of WRR (t~low~ = 3.5, *p* = 0.003; t~high~ = 6.1, *p* = 0.005). When the efficacy was assessed by means of ERR, a significant difference was only observed for high levels of infection intensity, CP450 being more efficacious than ALB (t = 3.5, *p* = 0.006). For low level infection intensity, there was no significant difference in ERR between CP450 and ALB (t = 1.71, *p* = 0.15).

Dose--response trial
--------------------

Table  [2](#T2){ref-type="table"} summarizes the number of animals, mean FEC at D-1, the mean FEC D+6, and WC at D7 for each of the five treatment groups (single-oral dose of 45, 115, 225 and 450 μmol CP \[CP45, CP115, CP225 and CP450\] and control) against high-intensity *T. suis* infections. All 30 animals (6 animals per treatment group) completed the trial. The mean FEC at D-1 ranged from 233.3 EPG (95% CI: 16.7; 558.3) for the CP115 group to 500.0 EPG (95% CI: 41.7; 1,200.0) for the CP45 group. There was no significant difference in FEC at D-1 across the different treatment groups (F = 0.219, *p* = 0.95). The mean WC at D+7 in the control animals was 856.3 (95%CI: 328.7; 1,384.0, recovery rate of 28.5% \[95% CI: 11.0; 46.1\]).

###### 

**The efficacy of four doses of papaya CPs against high intensity*T. suis*infections**

  **Treatment arm**   **n**   **Mean FEC at D-1 (EPG) (95% CI)**   **Mean FEC at D+6(EPG) (95% CI)**   **ERR (%) (95% CI)**   **Mean WC at D+7 (95% CI)**   **WRR (%) (95% CI)**
  ------------------- ------- ------------------------------------ ----------------------------------- ---------------------- ----------------------------- -----------------------
  CP45                6       500.0(41.7; 1,200)                   5416.7(2200.0; 9233.3)              2.1\*(-629.8; 68.9)    976.5(697.3; 1,256.1)         -14.0\*(-213.7; 36.1)
  CP115               6       233.3(16.7; 558.3)                   1425.0(183.3; 2908.3)               74.2(-98.1; 96.9)      278.5(64.7; 551.7)            67.5(-3.4; 93.9)
  CP225               6       241.7(50.0; 533.5)                   808.3(208.3; 1741.7)                85.4(-15.4; 97.1)      160.3(61.3; 265.8)            81.3(43.7; 93.9)
  CP450               6       441.7(25.0; 1,150.0)                 41.7(0.0; 108.3)                    99.2\*(93.6; 100)      8.5(2.7; 15.7)                99.0\*(97.0; 99.7)
  Control             6       308.3(33.3; 733.3)                   5533.3(758.3; 11608.3)              \_                     856.3(328.7; 1,384.0)         \_

The mean fecal egg counts (FEC) at day (D) -1, mean worm counts (WC) at D+7 and the reduction in WC at D+7 compared to the control group (WCR) for a single-oral dose of 45, 115, 225, and 450 μmol papaya CPs (P45, P115, P225 and P450).

\*pair-wise comparison between CP450 and CP45 revealed a significant difference with *p*-value \<0.01.

Overall, the efficacy measured by ERR and WRR increased as a function of increasing dose of CP. For ERR, the results ranged from 2.1% (95% CI: -629.8; 68.9) for a single oral dose of CP45 to 99.2% (95% CI: 93.6; 100) for a single oral dose of CP450. For WRR these results ranged from -14.0% (95% CI: -213.7; 36.1) to 99.0% (95% CI: 97.0; 99.7), respectively. As illustrated in Figure  [1](#F1){ref-type="fig"}, there was initially a relatively small fall in efficacy as the dose was reduced from CP450 to CP115, and then a steep drop in efficacy towards CP45. A single-oral dose CP450 was more efficacious compared to a single-oral dose of CP45 by means of both ERR (t = 2.7, *p* = 0.005) and WRR (t = 6.1, *p* = 0.001). The remaining pair-wise comparisons did not reveal a significant difference in efficacy (*p* \>0.12).

![**The efficacy of four doses of papaya CPs against high intensity*T. suis*infections assessed by means of egg reduction rate (black) and worm reduction rate (red).** Points represent mean values (n=6) and error bars show 95% CI with inserted values where bars extend beyond the Y-axis.](1756-3305-7-255-1){#F1}

FEC as a proxy for worm burden
------------------------------

Overall, there was high correlation (Rs = 0.80, *p* \<0.0001) between WC and FEC. However, as illustrated in Figure  [2](#F2){ref-type="fig"}, the relationship between these two variables was not linear, rather the FECs increased as an exponential function of WCs (R^2^ = 0.83).

![Scatterplots describing the fecal egg counts as a function of the worm counts.](1756-3305-7-255-2){#F2}

Discussion
==========

In the present study we conducted two randomized controlled efficacy trials to evaluate the efficacy of papaya CPs against experimental *T. suis* infections in pigs, and we clearly demonstrated that a single application of CPs at the higher doses used for treatment is far more effective than the most widely used synthetic anthelmintic. Therefore, this study confirms that papaya CPs have anthelminthic properties that are extremely effective against *Trichuris* infections. Here a single-oral dose of 450 μmol of papaya CPs reduced the egg excretion and worm burden by more than 97%, regardless of the level of infection intensity. These efficacy results are superior not only to the efficacy results of a single-oral dose of 400 mg ALB in the current study, but also to most ERR efficacy results reported in human populations for ALB and MEB, either administered in a single oral dose on one day (1×1 ALB: 64.5%; 1×1 MEB: 62.7%, Levecke et al., unpublished data), or even in several doses over consecutive days (2×1 ALB: 73.5%, 2×1 MEB: 87.1% \[[@B35]\], 3×1 ALB: 94.0%, 3×1 MEB: 97.3% \[[@B36]\], a double oral dose on 1 day (1×2 ALB: 94.8%, 1×2 MEB: 90.3% \[[@B37]\]. Single dose CP treatment was also considerably more effective in removing *T. suis* than any of the other compounds trialed in recent years (1× levamisol: 0% \[[@B38]\], 1× ivermectin: 86.8% \[[@B38]\], 1× tribendimidine: 31.1% \[[@B11]\], 1× nitazoxanide: 13.4% \[[@B12]\]) and drug combinations (1×1 ALB+MEB: 96.1%; 2×1 ALB+MEB: 97.3% \[[@B37]\], 1×1 ALB+ivermectin: 91.1% \[[@B38]\] and 97.5% \[[@B39]\]; ALB+diethylcarbamazine: 79.4% \[[@B39]\]; 2×1 ALB+nitazoxanide: 54.9% \[[@B35]\]; 1×1 MEB+levamisole: 85.0% \[[@B40]\]; 1×1 MEB+ivermectine: 96.7% \[[@B38]\]; pyrantel-oxantel: 86.9% \[[@B41]\].

Despite these promising results, there are some aspects that still need to be addressed before papaya CP can be considered as an acceptable alternative anthelminthic drug for MDA programs in the control of STH. These include formulation, dose and safety. At present, a dose 450 μmol papaya CPs represents a mass of \~45 g, and this poses an important obstacle in treating both human patients and animals but particularly a pediatric population due to the quantity of material. Nevertheless, given that the CPs used in the current work were contained entirely in a solution (unlike in some earlier work where gel-like latex was used, Stepek et al. \[[@B21]\], further concentration is possible, and a range of different vehicles/matrices can be exploited to generate a formulation and delivery system in a smaller volume that is more acceptable for oral delivery.

The dose--response trial indicated that the dose can be halved (225 μmol), without losing too much of its efficacy (\~99% vs. \~80%). Although this reduction in dose will also half the mass of CP, it still remains substantial (\~22 g) and in terms of weight and bulk, more than alternative, albeit less effective, treatments.

'Papain' has found various applications in the daily life of people and in the food industry, and is therefore widely available for these purposes, with less regulation than conventional medicines. However, the amounts of papain used by the consumer for these tasks are clearly much lower than the minimal dose that showed anthelmintic efficacy against trichuriasis in our trials (115 μmol or \~11 g). Some side effects of papaya CPs have been reported previously in animals and humans but these are relatively scarce. In the sheep trials reported by Buttle et al. \[[@B27]\], some oral blistering was observed, but this was not serious at the doses used \[[@B27]\]. Regurgitation of CP and their subsequent inhalation present a more serious threat, but again when administered to animals by well-trained staff oral delivery to mice did not result in losses. Novel formulations based on syrups would also most-likely eliminate this as a problem in treatment of people. CPs are proteins and there is also the risk of allergy developing to their frequent application. However, it should be emphasized here that the side effects have only been evaluated poorly to date and that this is one aspect of the use of papaya CPs that will have to be more thoroughly investigated before they can be marketed as anthelmintics.

The poor efficacy of ALB against *T. suis* (ERR: 59.0-64.4; WRR: 23.2-39.0) was not entirely unexpected, as the ERR results resemble those reported in a recent meta-analysis including five trials assessing the efficacy of a single oral-dose of 400 mg ALB in school children Cameroon, Ethiopia, Tanzania and Vietnam (ERR: 64.5% \[95% CI: 44.4; 84.7\]; Levecke et al., unpublished data). Although our results confirm the usefulness of pigs as a model for assessing drug efficacy against trichuriasis, we expected a more pronounced difference in efficacy across the two levels of infection intensity. The ERR for ALB against trichuriasis in the five aforementioned trials with school children ranged from 29.3% for a mean FEC at baseline of 1193 EPG, to 92.4% for a mean FEC at baseline of 420 EPG. In the current study, ALB provided comparable ERR results against low (mean FEC = 492 EPG, ERR = 64.4%) and heavy-intensity infections (mean FEC = 9267 EPG, ERR = 59.0%). Only for WRR was there a pronounced difference in efficacy (low: 23.2% vs. heavy: 39.0%).

Finally, our results indicate that egg excretion increased as a function of worm burden, suggesting that FEC are a valid proxy of worm burden for trichuriasis in pigs.

Conclusions
===========

A single dose of 450 μmol papaya CPs provided greater efficacy against *T. suis* infections in pigs than a single-oral dose of 400 mg ALB. Although these results highlight the possibility of papaya CPs being used to treat human trichuriasis further development is needed in order to obtain and validate an oral formulation for use in both human and veterinary medicine. Our results confirm the suitability of pigs as a model for assessing drug efficacy against trichuriasis. Finally, this study suggests that FEC are a valid proxy for worm burdens in this host-parasite system.
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